Histo-blood Group A/B Versus H Status of Human Carcinoma Cells As Correlated with Haptotactic Cell Motility: Approach with A and B Gene Transfection
Overview
Authors
Affiliations
In a search for the molecular basis of ABH status of tumors as correlated with malignancy, we studied various malignancy-related phenotypes of high H/Le(y)-expressing tumor cell lines in comparison with phenotypes of the same lines transfected with histo-blood group A or B genes. A and B gene transfectants, prepared independently from different H-active parental cells, showed A or B activity and abolition of H activity. All A and B gene transfectants, regardless of source, were characterized by significantly reduced Matrigel-dependent haptotactic motility. The level of haptotaxis of all transfectants was similar to that of parental cells in the presence of antibodies against human integrin subunits alpha3, alpha6, or beta1. These subunits showed high expression of A or B epitope in the A and B gene transfectants. Enhancement versus reduction of malignancy, associated with deletion versus induction of A/B epitopes, may be due in part to enhanced haptotaxis sustained by alpha3, alpha6, and beta1 integrin receptors, the activities of which are regulated by H or A/B glycosylation. These phenotypic changes provide a rationale for the deletion of A and B epitopes as one criterion defining human tumor malignancy.
ABO/Rh Blood Group and Cervical Cancer Survival: Results from Our Own and Other Studies.
Mandato V, Torricelli F, Mastrofilippo V, Vacca I, Melli B, Generali M J Cancer. 2024; 15(15):4777-4788.
PMID: 39132152 PMC: 11310867. DOI: 10.7150/jca.95245.
ABO Blood Group and the Risk and Prognosis of Lymphoma.
Qin L, Gao D, Wang Q, Zheng X, Wang J, Chen X J Inflamm Res. 2023; 16:769-778.
PMID: 36855543 PMC: 9968433. DOI: 10.2147/JIR.S401818.
Zouine S, Marnissi F, Otmani N, Bennani Othmani M, Zaid N, Kojok K J Breast Cancer. 2020; 23(1):69-79.
PMID: 32140271 PMC: 7043947. DOI: 10.4048/jbc.2020.23.e13.
Mandato V, Torricelli F, Mastrofilippo V, Ciarlini G, Pirillo D, Farnetti E J Cancer. 2017; 8(14):2828-2835.
PMID: 28928872 PMC: 5604215. DOI: 10.7150/jca.19524.
Ben Q, Liu J, Wang W, Guo F, Yao W, Zhong J Oncotarget. 2017; 8(33):54799-54808.
PMID: 28903383 PMC: 5589622. DOI: 10.18632/oncotarget.18592.